Premium
Euglycaemic diabetic ketoacidosis in patients using sodium‐glucose co‐transporter 2 inhibitors
Author(s) -
Isaacs Michelle,
Tonks Katherine T.,
Greenfield Jerry R.
Publication year - 2017
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13442
Subject(s) - medicine , diabetic ketoacidosis , ketoacidosis , diabetes mellitus , complication , transporter , type 2 diabetes mellitus , type 2 diabetes , drug class , endocrinology , intensive care medicine , type 1 diabetes , pharmacology , drug , biochemistry , chemistry , gene
Sodium‐glucose co‐transporter 2 inhibitors ( SGLT2i ) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis ( euDKA ) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication. We describe three cases of euDKA in patients treated with SGLT2i .